AstraZeneca ramps up AZD9291 lung cancer clinical development
Boston – At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the development of AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and wild type T790M mutations in non-small cell lung cancer (NSCLC).
Dr Galbraith reviewed the three abstracts presented at Molecular Targets and answered questions on the AZD9291 clinical data presented at ECCO 2013 in Amsterdam.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
4 Responses to “AstraZeneca ramps up AZD9291 lung cancer clinical development”
Good post!
Poor Clovis. How does the little guy compete? Is there’s likely to be better than AZN’s?
Good question, Angela. We don’t know yet, there are other compounds that reportedly target T790M such as Ariad’s AP26113 but haven’t seen much compelling data there yet. It’s too early to say, but good to have some agents targeting this subset.
Could be this an issue of mutant vs wild-type EGFR inhibition?
Yes… As far as I know, the T790M mutation only occurs as an adaptive response to EGFR therapy, which is given to lung cancer patients with the EGFR mutation, not wild-type. Around 40-50% of those receiving the EGFR therapy develop this specific mutation.
Comments are closed.